Navigation Links
ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells

ATHENS, Georgia, Aug. 19 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has entered into an exclusive worldwide technology licensing agreement with the University of Georgia Research Foundation that will enable the company to commercialize human mesenchymal cells developed at the University of Georgia.

(Logo: )

Under the terms of the agreement, ArunA has acquired an exclusive worldwide license to develop and commercialize human mesenchymal cells (hMSC(TM)) derived from human embryonic stem cells, a product never before available. ArunA will offer the academic and industrial research communities access to a highly uniform population of human mesenchymal cells grown as adherent monolayer cultures in multiple turn-key kit formats. The hMSC kits will provide a physiologically relevant and genetically stable source of research material for use in a broad range of life science research applications such as: developmental pathway studies, disease modeling, in vitro toxicology, compound screening and humanized animal models.

"ArunA's proprietary adherent monolayer culture technology creates millions of highly uniform cells. These unique cells provide researchers with new enabling tools that can have a measurable impact on the advancement of drug discovery," says ArunA Biomedical President and Chief Executive Officer, William Sharp. "We are targeting an early first quarter 2009 launch of ArunA's first hMSC kit."

According to Robert Nerem, the Parker H. Petit Distinguished Chair for Engineering in Medicine at the Georgia Institute of Technology, "One of the most important uses of human embryonic stem cells will be in the generation of uniform populations of adult stem cells and progenitor cells. It is thus exciting that ArunA Biomedical will be able to provide uniform cell populations of human mesenchymal cells in kit form. This not only will be of value to bench scientists, but also in advancement toward clinical therapies."

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases.

SOURCE ArunA Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
3. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
4. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
5. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
6. HIPAA Privacy Rule Impedes Biomedical Research
7. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
8. Environmental Tectonics Corporations BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers
9. The NCIIA Recognizes Collegiate Biomedical Engineering Innovations
10. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
11. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
(Date:11/24/2015)... -- SHPG ) announced today that Jeff Poulton ... th Annual Healthcare Conference in New York City ... EST (1:30 p.m. GMT). --> SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
(Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
(Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
Breaking Biology News(10 mins):